one
dramat
therapeut
advanc
histori
medicin
develop
clinic
implement
antiretrovir
therapi
art
hiv
infect
singular
achiev
convert
almost
univers
fatal
infect
manag
chronic
condit
provid
power
intervent
reduc
rate
advanc
origin
basic
understand
molecular
mechan
hiv
replic
standard
must
consid
quintessenti
paradigm
modern
benchtobedsid
research
translat
despit
accomplish
hiv
epidem
continu
grow
number
peopl
need
therapi
increas
faster
rate
number
peopl
access
care
moreov
even
resourcerich
region
major
hivinfect
peopl
diagnos
care
andor
effect
mani
factor
account
failur
includ
expens
therapi
side
effect
therapi
difficulti
adher
regimen
year
decad
tackl
epidem
perhap
end
aid
time
two
advanc
must
vaccin
effect
durabl
protect
risk
hiv
acquisit
therapi
erad
viru
alreadi
infect
need
effect
hiv
vaccin
appreci
sinc
identif
hiv
earli
possibl
cure
consid
sinc
advent
effect
art
decad
ago
progress
compel
need
slow
one
obviou
gener
differ
success
develop
art
lack
effect
vaccin
cure
strategi
solut
latter
two
problem
found
studi
hiv
hivinfect
cell
alon
instead
must
formul
analysi
complex
vivo
interact
viru
host
vaccin
develop
two
crucial
need
first
identifi
immunolog
vulner
hiv
easi
task
consid
hiv
simian
immunodefici
viru
precursor
evolv
effici
evad
immun
therefor
caus
chronic
activ
infect
second
develop
vaccin
approach
safe
durabl
exploit
cure
issu
even
complex
requir
understand
natur
homeostasi
hiv
reservoir
artsuppress
subject
develop
approach
activ
latent
viru
destroy
cell
harbor
replic
potenti
replic
wherea
aspect
pathophysiolog
investig
test
tube
attain
level
understand
necessari
ration
design
prophylact
vaccin
clinic
intervent
cure
requir
vivo
analysi
daunt
challeng
given
hiv
humanspecif
viru
resid
larg
difficulttoreach
tissu
infect
destroy
immun
system
lead
hostviru
interact
complex
difficult
imposs
untangl
despit
complex
human
studi
led
crucial
advanc
understand
hiv
transmiss
persist
exampl
recent
vaccin
trial
provid
evid
hiv
transmiss
might
vulner
vaccineelicit
immun
increas
number
monoclon
antibodi
isol
hivinfect
individu
unequivoc
show
humor
immun
system
gener
potent
broadli
hiv
neutral
antibodi
moreov
appar
cure
berlin
patient
identif
posttreat
hiv
show
hiv
reservoir
potenti
vulner
postart
control
perhap
clearanc
howev
capit
observ
continu
limit
inher
characterist
human
model
includ
restrict
abil
determin
caus
effect
activ
vivo
intervent
treatment
must
therapeut
potenti
accept
safeti
profil
fact
everi
human
infect
differ
viru
fact
research
often
limit
access
human
tissu
blood
addit
transmiss
analysi
natur
hiv
exposur
variabl
uncertain
determin
gener
retrospect
observ
intervent
studi
human
therefor
take
field
far
enough
rais
question
defin
desir
outcom
suffici
far
answer
question
provid
clear
path
therapeut
achiev
outcom
although
iter
adapt
clinic
trial
propos
solut
realiti
question
mani
accept
intervent
cover
necessari
base
unless
lucki
identifi
optim
effect
vaccin
cure
strategi
human
studi
alon
take
long
time
thu
first
step
develop
effect
vaccin
cure
strategi
invari
involv
use
relev
anim
model
although
aspect
hiv
pathophysiolog
model
human
use
model
studi
hiv
immuno
pathobiolog
base
nonhuman
mani
nonhuman
primat
aid
viru
model
exist
equival
model
appropri
everi
scientif
question
inde
misappl
model
lead
field
serious
astray
exampl
abil
respons
elicit
adenoviru
vaccin
vector
control
infect
sivhiv
hybrid
viru
protect
acut
diseas
caus
led
expect
hiv
version
vaccin
would
provid
substanti
clinic
protect
human
trial
adenoviru
vaccin
famous
fail
result
would
predict
analysi
inabl
vaccin
protect
chronic
aggress
siv
caus
infect
close
resembl
hiv
hindsight
suggest
mistak
limit
use
nonhuman
primat
model
past
group
size
small
lead
inconclus
studi
use
siv
challeng
dose
unrealist
high
vaccin
studi
particularli
via
intraven
rout
regard
recent
studi
use
repeat
limiteddos
mucos
challeng
close
reflect
human
sexual
transmiss
larger
group
size
reveal
immun
vulner
highli
pathogen
siv
could
appreci
previou
standard
approach
includ
vaccinemedi
protect
acquisit
highli
pathogen
siv
infect
clear
similar
protect
observ
human
vaccin
nonhuman
primat
small
human
consid
surrog
human
gatekeep
human
trial
howev
analysi
appropri
nonhuman
primat
model
defin
answer
crucial
question
relev
hiv
vaccin
develop
cure
well
explor
feasibl
efficaci
gener
approach
inde
given
complex
relev
scientif
issu
myriad
potenti
pathway
achiev
therapeut
success
argu
better
exploit
nonhuman
primat
system
well
develop
human
mous
model
requir
clear
need
coordin
nonhuman
primat
model
clinic
research
new
obstacl
progress
remain
nonhuman
primat
research
expens
thu
experi
appropri
statist
power
invari
exceed
cost
limit
common
fund
mechan
facil
expertis
appropri
experi
well
anim
quit
limit
creat
bottleneck
potenti
key
experi
underpow
delay
perform
translat
preclin
find
human
system
also
problemat
clinic
investig
face
number
barrier
success
gain
knowledg
hiv
transmiss
persist
therapi
requir
studi
mucos
lymphoid
tissu
group
routin
access
process
tissu
clinic
studi
increasingli
requir
team
clinic
basic
scientist
lead
uncertain
academ
advanc
pathway
sourc
support
translat
studi
new
concept
difficult
get
peer
review
typic
small
pilot
studi
investig
human
also
invari
involv
risk
deter
mani
funder
draw
attent
multipl
oversight
committe
lead
overwhelm
regulatori
hurdl
final
human
studi
aim
defin
biolog
hiv
infect
andor
select
therapi
futur
definit
clinic
trial
expens
requir
consider
fund
compar
laboratori
smallanim
project
increasingli
recogn
key
funder
hiv
vaccin
cure
research
tradit
academ
research
model
independ
laboratori
anim
modelbas
research
group
fund
small
project
research
grant
achiev
goal
hiv
vaccin
cure
agenda
one
key
challeng
field
adapt
cooper
multidisciplinari
nonhuman
primat
model
clinic
researchori
scienc
necessari
success
sd
make
influenza
virus
abl
effici
transmit
person
person
other
determin
virul
influenza
virus
influenza
caus
sever
diseas
peopl
other
best
respond
emerg
new
influenza
viru
question
focu
activ
research
influenza
research
face
number
specif
challeng
first
divers
influenza
virus
natur
limit
generaliz
find
one
strain
strain
subtyp
necessit
experi
differ
influenza
viru
backbon
second
although
sever
anim
model
support
replic
influenza
virus
extent
use
studi
diseas
transmiss
vari
avail
immunolog
reagent
character
host
respons
infect
addit
although
data
ferret
monkey
relev
human
data
mice
sampl
size
experi
speci
often
small
expens
purchas
hous
third
unpredict
occurr
sever
season
influenza
make
challeng
plan
execut
studi
welldesign
studi
may
yield
data
mild
influenza
season
therefor
prudent
plan
fund
clinic
studi
span
one
influenza
season
influenza
virus
constantli
evolv
reassort
mutat
infect
new
host
speci
evidenc
equin
influenza
virus
isol
dog
avian
influenza
virus
isol
pig
human
sporad
fail
spread
viru
spread
effici
newli
infect
speci
latter
occur
human
pandem
ensu
unfortun
yet
understand
viral
host
factor
determin
transmiss
influenza
virus
human
specif
caveat
one
studi
transmiss
human
influenza
virus
human
anim
influenza
virus
anim
despit
controversi
primarili
due
dualus
concern
surround
public
two
recent
studi
describ
mutat
virus
confer
transmiss
ferret
transmiss
influenza
virus
crucial
area
scientif
afford
set
asid
entir
one
possibl
approach
studi
transmiss
anim
influenza
virus
pandem
potenti
begin
hypothesi
test
lowvirul
virus
studi
rais
concern
experi
highli
pathogen
virus
limit
experi
highli
virul
viru
conduct
safe
appropri
contain
care
risk
assess
need
gener
definit
proof
studi
requir
commun
influenza
virologist
biosafeti
biosecur
expert
well
educ
scientif
gener
public
import
research
emphasi
safeguard
place
anim
model
use
answer
mani
question
influenza
biolog
rang
pathogenesi
immun
respons
transmiss
control
measur
model
pro
con
none
faith
replic
clinic
experi
human
part
gap
data
anim
model
clinic
experi
laboratori
research
carri
experiment
anim
wherea
human
beyond
earli
childhood
prior
experi
influenza
studi
anim
led
overestim
virul
pandem
viru
predict
two
dose
vaccin
would
requir
immun
popul
turn
result
previou
prime
singl
dose
vaccin
suffici
immun
young
children
prior
exposur
model
anim
model
judici
select
address
specif
research
question
rather
onesizefitsal
approach
data
ferret
nonhuman
primat
emphas
exclus
data
identif
viral
determin
virul
understand
event
trigger
host
lead
develop
new
therapeut
agent
viral
determin
virul
typic
identifi
compar
pair
influenza
virus
dichotom
virul
sequenc
experiment
anim
surveil
program
monitor
virus
genet
chang
associ
virul
challeng
lie
synthes
inform
focu
phenotyp
virul
rather
genotyp
explor
mutat
alter
virul
determin
whether
broadli
applic
uniqu
particular
isol
clade
influenza
caus
sever
diseas
peopl
other
multidisciplinari
approach
examin
influenc
genet
immunolog
virushost
interact
natur
histori
human
challeng
probabl
shed
light
question
human
challeng
studi
need
access
challeng
viru
prepar
meet
regulatori
requir
appropri
inpati
facil
mechan
maintain
pipelin
challeng
viru
pool
subject
suscept
requir
longterm
commit
fund
scientif
medic
public
health
commun
must
abl
respond
rapidli
emerg
novel
viru
way
network
place
activ
short
notic
good
exampl
mosaic
mechan
sever
acut
influenza
consortium
network
undertook
clinic
evalu
pandem
viru
despit
oper
hurdl
excit
time
influenza
research
increasingli
sophist
technolog
becom
avail
address
complex
question
biolog
medicin
public
health
ration
discours
applic
specif
model
elucid
biolog
mechan
underli
virul
transmiss
facilit
understand
human
influenza
method
search
unknown
viru
quick
answer
shortcut
quest
viral
diseas
etiolog
understand
viral
causat
key
diagnost
prevent
treatment
diseas
grow
discrep
expect
result
field
pose
crucial
question
must
address
learn
new
sequenc
new
technolog
nextgener
sequenc
first
differ
virus
viral
sequenc
must
discuss
clarifi
year
ago
earli
day
pcr
diagnost
phenomenon
reaction
product
hop
pcr
tube
left
virologist
hesit
accept
exist
new
virus
isol
obtain
character
advanc
technolog
use
nowaday
allow
us
find
sequenc
often
form
new
phylogenet
clade
clearli
differ
laboratori
strain
unlik
contamin
artifact
although
nextgener
sequenc
also
detect
integr
defect
virus
viral
genom
encount
new
sequenc
repres
true
virus
potenti
replic
caus
diseas
human
threshold
beyond
virus
declar
new
still
spark
continu
long
lack
gener
prospect
criteria
classifi
new
virus
improv
knowledg
viral
divers
obtain
viru
discoveri
howev
soon
enabl
much
gener
approach
viral
taxonomi
base
fullgenom
holist
taxonomi
function
implic
exampl
come
investig
cellular
antivir
target
whose
activ
could
conserv
within
reason
delin
taxonom
unit
clinic
viru
discoveri
plenti
studi
respiratori
ill
condit
virus
caught
redhand
bodi
diseas
multipl
sclerosi
chronic
degen
diseas
far
solv
mysteri
etiolog
viru
involv
may
long
gone
symptom
trace
virus
might
exist
immun
pattern
antibodi
prime
immun
cell
although
pattern
alreadi
investig
avail
method
seen
technic
revolut
immun
diagnost
molecular
detect
nextgener
sequenc
enhanc
depth
data
order
magnitud
therefor
technic
capabl
find
new
viru
sequenc
longer
bottleneck
instead
biggest
challeng
appreci
medic
relev
result
tradit
believ
virus
part
normal
flora
caus
sentiment
newli
discov
virus
pathogen
recent
studi
shown
normal
human
microbi
flora
probabl
includ
nonpathogen
even
symbiot
addit
innocu
contamin
virus
also
detect
human
plant
arthropod
fish
virus
like
deriv
viru
discoveri
studi
must
therefor
entail
appropri
clinic
valid
statist
power
confirm
absenc
new
virus
healthi
control
group
current
lack
data
pathogen
whole
rang
new
virus
includ
cardiovirus
klassevirussaliviru
cosavirus
sever
new
anello
circo
cyclovirus
small
singlestrand
dna
virus
well
expand
rang
new
polyomavirus
human
bocaviru
discov
heavili
investig
sinc
seen
paradigm
problemat
field
major
studi
human
bocaviru
focus
patient
diseas
studi
includ
suffici
rang
differenti
diagnos
found
tremend
rate
coinfect
plethora
profession
respiratori
enter
pathogen
suggest
viru
viru
discoveri
also
extend
anim
virus
investig
viral
reservoir
rais
big
expect
translat
valu
data
although
studi
aim
primarili
understand
ecolog
evolut
hope
big
promis
viru
discoveri
may
give
us
head
start
next
pandem
reason
endeavor
make
censu
virus
lurk
anim
reservoir
help
identifi
virus
futur
outbreak
exampl
expand
knowledg
batborn
coronavirus
made
identif
new
human
coronaviru
recent
emerg
arabian
peninsula
much
easier
identif
sar
coronaviru
year
sequenc
reservoirborn
virus
first
step
viral
risk
assess
complex
process
viral
entri
virushost
cooper
cellular
level
well
mani
compon
epitheli
system
host
defens
versu
viral
immun
evas
also
determin
whether
viru
infect
spread
human
unfilt
present
new
virus
creat
unjustifi
air
alarm
therefor
investig
biolog
function
provid
surrog
transmiss
risk
along
initi
descript
reservoirborn
virus
initi
studi
work
along
line
publish
descript
new
henipaviru
seem
lack
essenti
antiinterferon
protein
new
influenza
viru
bat
whose
replic
protein
seem
function
context
human
improv
viral
sequenc
inventori
may
address
one
largest
technic
challeng
current
encount
viral
discoveri
lack
templat
sequenc
compar
data
routin
see
nextgener
sequenc
read
align
known
member
public
gene
databas
genet
distanc
bank
viru
larg
still
genet
terra
incognita
recogn
nextgener
sequenc
read
viral
sequenc
short
read
also
preclud
sensit
databas
comparison
base
predict
encod
protein
structur
thu
even
though
collect
reservoir
anim
metavirom
seem
like
larg
effort
littl
direct
util
may
fact
constitut
direct
way
better
understand
human
virom
collect
current
approach
viral
discoveri
domin
fascin
around
new
technolog
evolv
rapid
pace
nevertheless
result
obtain
still
closer
raw
data
conclus
analys
etiolog
problem
clinic
function
investig
must
includ
routin
discoveri
studi
prevent
misinterpret
data
fulfil
elementari
translat
identif
meaning
viral
etiolog
respiratori
syncyti
viru
rsv
lead
caus
bronchiol
pneumonia
children
estim
rsv
infect
result
million
case
acut
lower
respiratori
diseas
children
less
year
old
requir
hospit
admiss
despit
year
intens
studi
vaccin
prevent
rsv
diseas
option
treatment
although
passiv
administr
virusneutr
antibodi
reduc
rsvrelat
hospit
infant
high
risk
rsv
translat
protect
correl
safe
effect
pediatr
vaccin
yet
occur
sever
problem
account
lack
success
highest
rate
rsv
hospit
among
infant
less
month
abil
elicit
strong
antibodi
respons
vaccin
may
compromis
presenc
matern
antibodi
immatur
infant
immun
system
addit
vaccin
format
might
capabl
elicit
strong
rsvneutral
serum
antibodi
respons
children
compar
achiev
antibodi
immunoprophylaxi
parenter
administr
properli
fold
viral
protein
subunit
formul
adjuv
would
difficult
clinic
develop
least
part
concern
vaccin
may
potenti
rsv
diseas
formalininactiv
alumadjuv
wholeviru
vaccin
test
infant
children
howev
fail
protect
rsv
diseas
also
result
immunemedi
diseas
subsequ
develop
anim
model
rsv
vaccin
diseas
enhanc
suggest
parenter
vaccin
anim
subunit
vaccin
could
result
enhanc
pulmonari
patholog
rsv
contrast
live
attenu
rsv
vaccin
chimer
virus
express
rsv
seem
enhanc
risk
rsv
diseas
vaccin
anim
live
intranas
administ
vaccin
candid
advanc
clinic
studi
seroneg
infant
clinicaltrialsgov
howev
identifi
immun
correl
activ
protect
probabl
difficult
live
intranas
vaccin
remain
local
airway
infant
intranas
vaccin
live
attenu
rsv
vaccin
candid
detect
serum
antibodi
rsv
spite
evid
vaccin
recipi
protect
subsequ
challeng
vaccin
past
experi
live
attenu
influenza
vaccin
illustr
difficulti
identifi
correl
protect
vaccin
administ
local
numer
assay
evalu
past
year
includ
variou
measur
serum
antibodi
respons
nasal
iga
enzymelink
immunospot
assay
howev
date
absolut
correl
protect
identifi
influenza
vaccin
problem
may
current
assay
system
insuffici
sensit
detect
local
immun
respons
although
possibl
develop
vaccin
without
correl
activ
challeng
inabl
show
vaccin
induc
robust
immun
respons
major
recipi
make
decis
proceed
larg
expens
efficaci
studi
difficult
vaccin
licens
correl
immun
protect
establish
demonstr
subsequ
manufactur
andor
formul
modif
neg
impact
vaccin
potenc
requir
conduct
addit
efficaci
studi
would
highli
desir
rsv
therapeut
capabl
reduc
diseas
sever
halt
diseas
progress
andor
shorten
time
diseas
resolut
rsvinfect
children
diagnos
especi
import
continu
absenc
rsv
vaccin
central
concern
rsv
antivir
develop
howev
whether
antivir
compound
affect
diseas
progress
outcom
administ
child
symptomat
recent
studi
rsv
infect
us
indic
children
brought
emerg
depart
pediatr
offic
often
alreadi
moder
sever
propos
rsv
pathogenesi
involv
airway
obstruct
exud
contain
damag
epitheli
cell
driven
viral
replic
host
immun
respons
infect
target
one
would
fail
provid
therapeut
benefit
much
understand
rsv
pathogenesi
role
host
respons
rsv
patholog
come
mous
cotton
rat
infect
model
anim
model
imperfect
best
unlik
accur
reflect
diseas
progress
children
continu
debat
whether
rsv
replic
drive
diseas
respiratori
symptom
appar
may
discourag
develop
new
antivir
compound
rsv
antivir
capabl
shut
viru
replic
like
effect
later
diseas
cours
agent
design
block
viru
entri
spread
clinic
test
replic
inhibitor
driver
rsv
diseas
may
elucid
furthermor
agent
act
viru
host
may
provid
safest
strategi
treat
young
children
rsv
diseas
although
rsv
larg
known
pediatr
infect
also
caus
substanti
diseas
elderli
adult
chronic
heart
lung
diseas
immunosuppress
specif
cell
humor
respons
rsv
seem
intact
adult
like
effect
vaccin
strategi
target
adult
popul
differ
infant
presenc
rsvneutral
antibodi
adult
would
prevent
infect
upper
airway
live
attenu
rsv
vaccin
develop
seroneg
children
develop
therapeut
intervent
adult
requir
rapid
diagnost
appropri
popul
adult
shed
lower
quantiti
viru
shorter
period
time
compar
mani
rsv
diagnost
develop
pediatr
differ
commerci
rsv
diagnost
kit
insuffici
sensit
detect
rsv
adult
pcr
methodolog
allow
detect
rsv
adult
extrem
sensit
led
observ
investig
persist
rsv
infect
particularli
adult
chronic
obstruct
pulmonari
persist
infect
rsv
remain
controversi
topic
substanti
found
clinic
meaning
could
profound
implic
develop
rsv
vaccin
therapi
rsv
complex
pathogen
pose
multipl
translat
challeng
includ
lack
smallanim
model
recapitul
human
infect
diseas
differ
human
target
popul
requir
differ
diagnost
intervent
strategi
fact
pathogenesi
immun
respons
must
studi
rather
inaccess
compart
human
airway
case
complex
pathogen
consolid
data
multipl
sourc
independ
provid
incomplet
pictur
along
applic
new
technolog
platform
lead
vaccin
therapi
rsv
addit
rsv
larg
affect
young
old
success
rsv
requir
commit
better
understand
immun
respons
infect
earli
late
life
